Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 @ http://www.researchmoz.us/type-2-diabetes-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019-report.html

1. Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to
Drive Growth by 2019
GBI Research has released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Market
to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by
2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2
diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus,
which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019,
the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors)
are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and
thiazolidinediones.
Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are
expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is
expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the
prevalent population, GBI Research believes that the value of the global market has the potential to grow to
reach $38.8 billion by 2019.
Scope
A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety,
efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map
comparing major drugs in terms of safety, efficacy and dosing parameters. Comprehensive review of the
pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs
that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase
distribution, molecule types and molecular targets. Additional in-depth analysis of pipeline drug clinical trials
by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and
mechanism of action Multi-scenario forecast data for the market up to 2019, taking into account how it will be
affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease
epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and
Spain Discussion of the drivers and barriers for market growth
Reasons to Buy
Understand the many different types of type 2 diabetes therapies on the market, from the older, established
classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
Understand the strengths and weaknesses of each product Understand the scope of the pipeline, including
which molecule types and mechanisms of action are prominent Observe trends in clinical trial duration and
size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk
profiles of current and/or future developmental programs for type 2 diabetes therapeutics Assess the potential
clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics
market.
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

2. table Of Content
1 Table Of Contents 1
1.1 List Of Tables 5
1.2 List Of Figures 6
2 Executive Summary 7
2.1 A Highly Competitive And Growing Market 7
2.2 Strong Pipeline Containing A Diverse Set Of Products 8
3 Introduction 9
3.1 Epidemiology 9
3.2 Symptoms 9
3.3 Etiology 10
3.4 Pathophysiology 10
3.5 Co-morbidities And Complications 11
3.6 Classification 12
3.7 Prognosis 13
3.8 Diagnosis 13
3.9 Assessing Treatment Effectiveness 15
3.10 Treatment Algorithm 15
3.10.1 The Role Of Insulin In Type 2 Diabetes 17
3.10.2 Non-insulin Diabetic Drugs 18
3.10.3 Other Drugs 20
3.11 Gbi Research Report Guidance 20
4 Key Marketed Products 21
4.1 Dpp-4 Inhibitors 21
4.1.1 Januvia (sitagliptin) – Merck & Co 21
4.1.2 Tradjenta (linagliptin) – Boehringer Ingelheim 23
4.1.3 Onglyza (saxagliptin) – Bristol-myers Squibb And Astrazeneca 24
4.1.4 Nesina (alogliptin) – Takeda 24
4.1.5 Galvus (vildagliptin) – Novartis 25
4.2 Glp-1 Agonists 26
4.2.1 Byetta And Bydureon (exenatide) – Bristol-myers Squibb 26
4.2.2 Lyxumia (lixisenatide) – Sanofi 27
4.2.3 Victoza (liraglutide) – Novo Nordisk 28
4.3 Sulfonylureas 28
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

3. 4.3.1 Glimepiride 28
4.3.2 Gliclazide 29
4.4 Thiazolidinediones 30
4.4.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 30
4.4.2 Avandia (rosiglitazone) – Glaxosmithkline 31
4.5 Other 32
4.5.1 Metformin 32
4.5.2 Lantus (insulin Glargine) – Sanofi 33
4.5.3 Levemir (insulin Detemir) – Novo Nordisk 34
4.5.4 Forxiga (dapagliflozin) – Bristol-myers Squibb 35
4.6 Heat Map For Marketed Products 35
5 Pipeline For Type 2 Diabetes 39
5.1 Overall Pipeline 39
5.2 Therapeutic Classes 40
5.3 Rate Of Attrition 42
5.3.1 Failure Rate By Molecule Type 42
5.3.2 Failure Rate By Therapeutic Class 44
5.4 Reasons For Failure Of Developmental Programs 46
5.5 Clinical Trial Duration 46
5.5.1 Duration By Molecule Type 46
5.5.2 Duration By Therapeutic Class 47
5.6 Clinical Trial Size 48
5.6.1 Clinical Trial Size By Molecule Type 49
5.6.2 Clinical Trial Size By Therapeutic Class 51
5.7 Promising Drugs In The Pipeline 53
5.7.1 Ly-2189265 (dulaglutide) – Eli Lilly 53
5.7.2 Albiglutide – Glaxosmithkline 53
5.7.3 Lc15-044 (gemigliptin) – Lg Life Sciences 54
5.7.4 Tak-875 – Takeda 54
5.7.5 Ipragliflozin – Astellas Pharma 55
5.7.6 Lx-4211 – Lexicon Pharmaceuticals 55
5.7.7 Imeglimin – Poxel Sa 56
5.7.8 Ccx-140-b – Chemocentryx 56
5.7.9 Semaglutide – Novo Nordisk A/s 57
5.7.10 Pc-dac Exendin-4 – Conjuchem Biotechnologies 57
5.8 Heat Map For Pipeline Products 57
5.9 Conclusion 60
6 Market Forecast To 2019 62
6.1 Global Market 62
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

4. 6.1.1 Treatment Usage Patterns 62
6.1.2 Market Size 63
6.2 Us 64
6.2.1 Treatment Usage Patterns 64
6.2.2 Annual Cost Of Therapy 65
6.2.3 Market Size 65
6.3 Top Five Countries Of Europe 66
6.3.1 Treatment Usage Patterns 66
6.3.2 Annual Cost Of Therapy 67
6.3.3 Market Size 68
6.4 Japan 69
6.4.1 Treatment Usage Patterns 69
6.4.2 Annual Cost Of Therapy 70
6.4.3 Market Size 70
6.5 Drivers And Barriers 71
6.5.1 Drivers 71
6.5.2 Barriers 71
7 Deals And Strategic Consolidations 72
7.1 Licensing Deals 72
7.1.1 Transtech Pharma Enters Into Licensing Agreement With Forest Laboratories 74
7.1.2 Xoma Enters Into Licensing Agreement With Les Laboratoires Servier For Xoma 052 75
7.1.3 Zealand Pharma Enters Into A Licensing And Collaboration Agreement With Boehringer Ingelheim 75
7.1.4 Exelixis Enters Into Licensing Agreement With Bristol-myers Squibb For Xl475 75
7.1.5 Prosidion Limited Enters Into A Licensing Agreement With Eli Lilly And Company 76
7.1.6 Metabolex Enters Into Licensing Agreement With Sanofi 76
7.1.7 Wellstat Enters Into A License Agreement With Sanofi 76
7.1.8 Curedm And Lankenau Institute Enter Into A Licensing Agreement With Sanofi 76
7.1.9 Metabolex Enters Into A Development And Licensing Agreement With Janssen Pharmaceuticals 76
7.1.10 Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Intercept Pharma For Int-747 77
7.1.11 Ipsen Enters Into Licensing Agreement With F. Hoffmann-la Roche For Bim 51077 77
7.1.12 Glenmark Pharma Enters Into Licensing Agreement With Merck Kgaa 77
7.1.13 Euroscreen Enters Into Licensing Agreement With Janssen Pharmaceuticals 77
7.1.14 Phenomix Enters Into Licensing Agreement With Chiesi Farmaceutici 78
7.1.15 Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 78
7.1.16 Nastech Pharma Enters Into Licensing Agreement With Amylin Pharma 78
7.1.17 Emisphere Technologies Enters Into A Licensing Agreement With Novo Nordisk 78
7.1.18 Array Biopharma Enters Into A Licensing Agreement With Amgen 78
7.1.19 Theratechnologies Enters Into A Licensing Agreement With Octoplus 79
7.1.20 Diabetica Enters Into A Licensing Agreement With Amylin 79
7.1.21 Celtic Therapeutics Enters Into A Licensing Agreement With Bellus Health 79
7.1.22 Aradigm Enters Into A Licensing Agreement With Novo Nordisk 79
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

5. 7.1.23 Santarus Enters Into A License Agreement With Shore Therapeutics 80
7.1.24 Depomed Enters Into A Licensing Agreement With Boehringer Ingelheim 80
7.1.25 Depomed Enters Into A Licensing Agreement With Merck 80
7.1.26 Depomed Enters Into A Licensing Agreement With Teva 80
7.2 Co-development Deals 81
7.2.1 Eli Lilly Enters Into A Co-development Agreement With Boehringer Ingelheim 82
7.2.2 Astrazeneca Enters Into Co-development Agreement With Bristol-myers Squibb 82
7.2.3 Metabolex Enters Into A Co-development Agreement With Janssen Pharmaceuticals 83
7.2.4 Amylin Pharma Terminates Co-development Agreement With Eli Lilly For Exenatide 83
7.2.5 Isis Enters Into A Collaboration Agreement With Janssen Pharmaceuticals 83
7.2.6 Neurocrine Biosciences Enters Into A Collaboration Agreement With Boehringer Ingelheim 84
7.2.7 Intercept Pharma Enters Into Co-development Agreement With Servier 84
7.2.8 Transition Therapeutics Enters Into An Agreement With Eli Lilly 84
7.2.9 Ambrx Enters Into A Co-development Agreement With Bristol-myers Squibb 84
7.2.10 Biocompatibles Enters Into A Co-development Agreement With Astrazeneca 85
8 Appendix 86
8.1 All Pipeline Drugs By Stage Of Development 86
8.1.1 Discovery 86
8.1.2 Preclinical And Ind-filed 88
8.1.3 Phase I 92
8.1.4 Phase Ii 95
8.1.5 Phase Iii And Pre-registration 98
8.1.6 Undisclosed 101
8.2 Market Forecasts To 2019 102
8.2.1 Global 102
8.2.2 Us 102
8.2.3 Uk 103
8.2.4 France 103
8.2.5 Germany 104
8.2.6 Italy 104
8.2.7 Spain 105
8.2.8 Japan 105
8.3 Market Definitions 106
8.4 Abbreviations 106
8.5 References For Heat Maps 108
8.6 References 111
8.7 Research Methodology 116
8.7.1 Coverage 116
8.7.2 Secondary Research 117
8.7.3 Primary Research 117
8.7.4 Therapeutic Landscape 117
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

6. 8.7.5 Epidemiology-based Forecasting 118
8.7.6 Pipeline Analysis 120
8.7.7 Expert Panel Validation 120
8.7.8 Contact Us 120
9 Disclaimer 120
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019